Quest Diagnostics announced the launch of the first clinical test panel for aiding the diagnosis of suspected dementia due to treatable forms of cognitive impairment. This diagnostic panel serves to combine several guideline-recommended tests for identifying secondary, treatable causes of dementia as a single blood test and report.
The new test is modeled after the recommendations of the AAN, AGA, NIHCP, and the EFNS. It evaluates a patient presenting with cognitive impairment for potentially reversible causes such as vitamin B12 deficiency, hypothyroidism, anemia and diabetes, based on lab test results. Patients with abnormal results may respond to treatment administered by a physician to reverse the underlying cause of dementia. Patients with normal results may require evaluation by a neurologist for other possible causes such as Alzheimer’s disease.
The test will be unveiled during the AAN Annual Meeting (March 16–23, 2013) in San Diego, CA.
For more information call (866) 697-8378 or visit www.questdiagnostics.com.